BACKGROUND: Administration of ghrelin to women stimulates the secretion of PRL but the mechanism is not known. AIM: The aim of the study was to investigate the effect of the dopamine receptor blocker, metoclopramide, on ghrelin-induced PRL release. SUBJECTS AND METHODS: Ten healthy normally cycling women were studied in the midluteal phase of 4 menstrual cycles. A single dose of normal saline (cycle 1), ghrelin (1 μg/kg) (cycle 2), metoclopramide (20 mg) (cycle 3), and ghrelin plus metoclopramide (cycle 4) was given to the women iv. Blood samples in relation to the iv injection (time 0) were taken at -15, 0, 15, 30, 45, 60, 75, 90, and 120 min. The response of PRL and GH was assessed. RESULTS: Following ghrelin administration (cycles 2 and 4), plasma ghrelin and serum PRL and GH levels increased rapidly, peaking at 30 min (p<0.001). PRL was also increased after the injection of metoclopramide (p<0.001, cycle 3), but the increase was much greater than after the administration of ghrelin. The combination of ghrelin and metoclopramide stimulated PRL secretion to the same extent with metoclopramide alone. No changes in GH and PRL levels were seen after saline injection. CONCLUSIONS: These results demonstrate that the stimulating effect of ghrelin on PRL secretion is not additive with that of metoclopramide, although a dose range study might provide further information.
BACKGROUND: Administration of ghrelin to women stimulates the secretion of PRL but the mechanism is not known. AIM: The aim of the study was to investigate the effect of the dopamine receptor blocker, metoclopramide, on ghrelin-induced PRL release. SUBJECTS AND METHODS: Ten healthy normally cycling women were studied in the midluteal phase of 4 menstrual cycles. A single dose of normal saline (cycle 1), ghrelin (1 μg/kg) (cycle 2), metoclopramide (20 mg) (cycle 3), and ghrelin plus metoclopramide (cycle 4) was given to the women iv. Blood samples in relation to the iv injection (time 0) were taken at -15, 0, 15, 30, 45, 60, 75, 90, and 120 min. The response of PRL and GH was assessed. RESULTS: Following ghrelin administration (cycles 2 and 4), plasma ghrelin and serum PRL and GH levels increased rapidly, peaking at 30 min (p<0.001). PRL was also increased after the injection of metoclopramide (p<0.001, cycle 3), but the increase was much greater than after the administration of ghrelin. The combination of ghrelin and metoclopramide stimulated PRL secretion to the same extent with metoclopramide alone. No changes in GH and PRL levels were seen after saline injection. CONCLUSIONS: These results demonstrate that the stimulating effect of ghrelin on PRL secretion is not additive with that of metoclopramide, although a dose range study might provide further information.
Authors: K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: H Rubinfeld; M Hadani; J E Taylor; J Z Dong; J Comstock; Y Shen; D DeOliveira; R Datta; M D Culler; I Shimon Journal: Eur J Endocrinol Date: 2004-12 Impact factor: 6.664
Authors: Petra Kok; Ferdinand Roelfsema; Marijke Frölich; Johannes van Pelt; A Edo Meinders; Hanno Pijl Journal: J Clin Endocrinol Metab Date: 2008-06-17 Impact factor: 5.958
Authors: Regina Célia Teixeira Gomes; Carina Verna; Ricardo S Simões; Roberta B Wolff; Edmund C Baracat; José Maria Soares Journal: Clinics (Sao Paulo) Date: 2011 Impact factor: 2.365
Authors: Mehdi Farokhnia; Kelly M Abshire; Aaron Hammer; Sara L Deschaine; Anitha Saravanakumar; Enoch Cobbina; Zhi-Bing You; Carolina L Haass-Koffler; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Int J Neuropsychopharmacol Date: 2021-07-14 Impact factor: 5.176